Clinical Trials

If you would like more information about any of these available clinical trials, or if you know a patient who you think would qualify, please call Jeanetta at 903-531-8850 or call our office at 903-597-CARE (2273).

NSC Lung

1. IMC-1121B: An open-Label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-Line Treatment of Patients with Recurrent or Advanced Non-Small Cell Lung Cancer(NSCLC)

Must have Stage 4 measurable disease
Can be squamous or nonsquamous
ECOG 0-2
Life expectancy of > or = 3 months
There are 4 arms to this study the investigator can choose between Cisplatin and Carboplatin in all 4 arms.

2. Amgen 20070782: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Evary-3-Weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy

ECOG 0-1
HBG < or = 11.0 g/dL
No brain mets

Breast

3. The EXTENET Study 3144A2-3004-WW: A Randomized Double-Blind, Placebo Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early Stage HER-2/Neu Overexpressed/Amplified Breast Cancer.

Her positive and must have finished Herceptin within the past 12 months
Diagnosis of Stage 2-3c
No metastatic disease

4. Z-ACT Study: CZOL446EUS147: A Multicenter, Randomized Trial to Evaluate the Anti-Cancer Effects of Zoledronic Acid Using Circulating Tumor Cell Measurements in Patients with Newly Diagnosed Her2-Negative Metastatic Breast Cancer.

Stage 4 breast cancer
No prior treatment with IV bisphosphonates
Prior chemo is ok in adjuvant or neoadjuvant setting but must have been completed 12 months prior to relapse

Multiple Myeloma

5. Connect MM: The Multiple Myeloma Registry.

Newly diagnosed within 2 months
Able to speak and read English
Able to fill out questionnaires every 3 months
(patient receives a $10 Visa gift card for every questionnaire)

CLL

6. Connect CLL: The Chronic Lymphocytic Leukemia Disease Registry.

CLL starting any line of chemo
Must be enrolled within 2 months of starting new chem.
Able to speak and read English
Able to fill out questionnaires every 3 months
(patient receives a $10 Visa gift card for every questionnaire)

Prostate

7. Saturn Study: OGX-011-10: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Curtirsen to Docetaxel Retreatment/Prednisone as an Option for Second-Line Therapy in Men with Castrate Resistant Prostate Cancer.

Must have received at least 5 cycles Docetaxel 1st line (q 3 weeks) and had a measured response
Must have been at least 6 weeks since last dose of Docetaxel
Must be on an stable opioid analgesic regimen that is related to cancer pain.

Colon

8. CP20-0801: An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) in Combination With IMC-1121B or IMC-18F1 or Without Investigational Therapy as Second-Line Therapy in Patients with Metastatic Colorectal Cancer Following Disease Progression on First-Line Irinotecan-based Therapy.

Must have disease progression after having irinotecan 1st line
ECOG 0-1
No brain mets

T-Cell Lymphoma

9. PTCL Registry: Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma.

Newly diagnosed T-Cell lymphoma

Pancreatic

(This study will not be open until November)

10. KLT-PANC-001: A Randomized Dose Escalation, Safety and Exploratory Efficacy Study of Kanglaite Injection plus Gemcitabine (G+K) versus Gemcitabine in Patients with Advanced Pancreatic Cancer.

Metastatic pancreatic cancer not resectable
ECOG 0-1
Must have a central venous catheter